GlaxoSmithKline GSK, a British pharmaceutical company, said Thursday that it would take a second quarter charge of $2.36 billion related to legal cases involving its drugs Avandia and Paxil.
An American medical advisory panel recommended Wednesday that Avandia, a diabetes drug, should either be withdrawn from the market or have sales significantly restricted because it increases the risk of heart attacks.
GlaxoSmithKline noted that the charge "includes provisioning for settled cases and an estimate for those cases which we have received and are still outstanding.”
Shares of GlaxoSmithKline are up 2% in early trade this morning.
You Can't Afford Miss Out On These Money Making Trading Ideas
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in